Disclaimer: This site aggregates publicly available data from official government sources (FDA, ClinicalTrials.gov, PubMed, SEC EDGAR, NMPA) for general reference only. It does NOT constitute medical advice, diagnosis, treatment recommendations, or investment advice.

Clinical Trial

Tolerance of nHFPV Versus nCPAP in Neonatal Respiratory Distress

NCT: NCT02030691 · COMPLETED

NCT IDNCT02030691
StatusCOMPLETED
Start Date2014-05
Completion2016-11-07

Brief Summary

Respiratory distress is the main cause of morbimortality in preterm and term neonates. In most of the case, these babies required the use of positive end expiratory pressure (PEEP) delivered by a non invasive device. Nasal continuous airway positive pressure (nCPAP) is widely used in neonatal intensive care unit. Nasal high frequency percussive ventilation (nHFPV) can be used as non invasive device to deliver PEEP, and improved lung clearance. We hypothesized that nHFPV can be used to deliver PEEP in preterm and term newborn with respiratory distress with the same tolerance as nCPAP. To compare the tolerance of these devices we used cerebral tissue oxygenation (rSO2c) measured by near infrared spectroscopy (NIRS).

Frequently Asked Questions

What is Tolerance of nHFPV Versus nCPAP in Neonatal Respiratory Distress?

Tolerance of nHFPV Versus nCPAP in Neonatal Respiratory Distress is a clinical trial registered under NCT02030691. Current status: COMPLETED.

What is the status of NCT02030691?

The current status of NCT02030691 (Tolerance of nHFPV Versus nCPAP in Neonatal Respiratory Distress) is: COMPLETED.

When did Tolerance of nHFPV Versus nCPAP in Neonatal Respiratory Distress start?

Tolerance of nHFPV Versus nCPAP in Neonatal Respiratory Distress started on 2014-05.

Official Source

View on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.